Stock Research: Ypsomed

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ypsomed

SWX:YPSN CH0019396990
56
  • Value
    42
  • Growth
    71
  • Safety
    Safety
    22
  • Combined
    34
  • Sentiment
    80
  • 360° View
    360° View
    56
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ypsomed Holding AG manufactures injection pens for pharmaceutical and biotech companies. It operates in the healthcare industry, specializing in injection systems and diabetes care. Ypsomed operates in Europe. In the last fiscal year, the company had a market cap of $7,127 million, profits of $330 million, and revenue of $847 million, with 2644 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 56 (better than 56% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ypsomed are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Ypsomed. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 71% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 80, which means that professional investors are more optimistic about the stock than for 80% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 22, which means that the share price of Ypsomed is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 78% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 42, which means that the company has a financing structure that is riskier than those of 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
SPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
22 20 15 41
Growth
71 86 99 69
Safety
Safety
42 46 48 12
Sentiment
80 58 87 56
360° View
360° View
56 61 73 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
75 51 72 46
Opinions Change
59 50 50 50
Pro Holdings
n/a 60 84 80
Market Pulse
69 65 80 24
Sentiment
80 58 87 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
22 20 15 41
Growth
71 86 99 69
Safety Safety
42 46 48 12
Combined
34 43 56 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
26 26 14 18
Price vs. Earnings (P/E)
7 7 12 46
Price vs. Book (P/B)
9 6 9 36
Dividend Yield
60 50 47 49
Value
22 20 15 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
39 94 84 81
Profit Growth
87 41 96 90
Capital Growth
75 91 45 12
Stock Returns
41 60 97 61
Growth
71 86 99 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
46 57 66 42
Refinancing
5 4 5 5
Liquidity
85 81 65 37
Safety Safety
42 46 48 12

Similar Stocks

Discover high‑ranked alternatives to Ypsomed and broaden your portfolio horizons.

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

SoftwareONE Holding

SWX:SWON
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.